Anticoagulants Market (By Route of Administration: Oral , Injectable; By Drug Class: Factor XA Inhibitors (NOAC/DOAC), Heparins, Direct Thrombin Inhibitors, Vitamin K Antagonists; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies; By Indication: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation, Heart Attack) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
       1.1.1. Definition of Anticoagulants
       1.1.2. Market Segmentation
       1.1.3. List of Abbreviations
1.2. Summary
       1.2.1. Market Snapshot
       1.2.2. Anticoagulants Market By Route of Administration
                 1.2.2.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Route of Administration (2015-2026)
                 1.2.2.2. Global Anticoagulants Market Revenue Share By Route of Administration in 2017
                 1.2.2.3. Oral
                 1.2.2.4. Injectable
       1.2.3. Anticoagulants Market By Drug Class
                 1.2.3.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
                 1.2.3.2. Global Anticoagulants Market Revenue Share By Drug Class in 2017
                 1.2.3.3. Factor XA Inhibitors (NOAC/DOAC)
                 1.2.3.4. Heparins
                 1.2.3.5. Direct Thrombin Inhibitors
                 1.2.3.6. Vitamin K Antagonists
       1.2.4. Anticoagulants Market By Distribution Channel
                 1.2.4.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
                 1.2.4.2. Global Anticoagulants Market Revenue Share By Distribution Channel in 2017
                 1.2.4.3. Hospital Pharmacies
                 1.2.4.4. Retail Pharmacies
                 1.2.4.5. Online Pharmacies
       1.2.5. Anticoagulants Market By Indication
                 1.2.5.1. Global Anticoagulants Market Revenue and Growth Rate Comparison By Indication (2015-2026)
                 1.2.5.2. Global Anticoagulants Market Revenue Share By Indication in 2017
                 1.2.5.3. Deep Vein Thrombosis (DVT)
                 1.2.5.4. Pulmonary Embolism (PE)
                 1.2.5.5. Atrial Fibrillation
                 1.2.5.6. Heart Attack
       1.2.6. Anticoagulants Market by Geography
                 1.2.6.1. Global Anticoagulants Market Revenue and Growth Rate Comparison by Geography (2015-2026)
                 1.2.6.2. North America Anticoagulants Market Revenue and Growth Rate (2015-2026)
                 1.2.6.3. Europe Anticoagulants Market Revenue and Growth Rate (2015-2026)
                 1.2.6.4. Asia-Pacific Anticoagulants Market Revenue and Growth Rate (2015-2026)
                 1.2.6.5. Latin America Anticoagulants Market Revenue and Growth Rate (2015-2026)
                 1.2.6.6. Middle East and Africa (MEA) Anticoagulants Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
       2.4.1. Bargaining Power of Suppliers
       2.4.2. Bargaining Power of Buyers
       2.4.3. Threat of Substitute
       2.4.4. Threat of New Entrants
       2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
       2.6.1. Raw Material and Suppliers
       2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
       2.8.1. Player Positioning Analysis
       2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Anticoagulants Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Anticoagulants Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Anticoagulants Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Anticoagulants Major Manufacturers in 2017

CHAPTER 4. ANTICOAGULANTS MARKET BY ROUTE OF ADMINISTRATION

4.1. Global Anticoagulants Revenue By Route of Administration
4.2. Oral
       4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Injectable
       4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ANTICOAGULANTS MARKET BY DRUG CLASS

5.1. Global Anticoagulants Revenue By Drug Class
5.2. Factor XA Inhibitors (NOAC/DOAC)
       5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Heparins
       5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Direct Thrombin Inhibitors
       5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Vitamin K Antagonists
       5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ANTICOAGULANTS MARKET BY DISTRIBUTION CHANNEL

6.1. Global Anticoagulants Revenue By Distribution Channel
6.2. Hospital Pharmacies
       6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
       6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
       6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. ANTICOAGULANTS MARKET BY INDICATION

7.1. Global Anticoagulants Revenue By Indication
7.2. Deep Vein Thrombosis (DVT)
       7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Pulmonary Embolism (PE)
       7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Atrial Fibrillation
       7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.5. Heart Attack
       7.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
       7.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. NORTH AMERICA ANTICOAGULANTS MARKET BY COUNTRY

8.1. North America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
       8.3.1. U.S. Anticoagulants Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       8.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
       8.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Canada
       8.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       8.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
       8.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. Mexico
       8.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       8.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       8.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
       8.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 9. EUROPE ANTICOAGULANTS MARKET BY COUNTRY

9.1. Europe Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
       9.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       9.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
       9.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
       9.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Germany
       9.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       9.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5. France
       9.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       9.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.6. Spain
       9.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       9.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.7. Rest of Europe
       9.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
       9.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)

CHAPTER 10. ASIA-PACIFIC ANTICOAGULANTS MARKET BY COUNTRY

10.1. Asia-Pacific Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
         10.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         10.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         10.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. Japan
         10.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         10.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         10.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. India
         10.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         10.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         10.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.6. Australia
         10.6.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         10.6.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         10.6.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.7. South Korea
         10.7.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         10.7.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         10.7.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
         10.8.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         10.8.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         10.8.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         10.8.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. LATIN AMERICA ANTICOAGULANTS MARKET BY COUNTRY

11.1. Latin America Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
         11.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         11.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         11.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         11.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Argentina
         11.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         11.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million
         11.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         11.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million))
11.5. Rest of Latin America
         11.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         11.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         11.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         11.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. MIDDLE EAST ANTICOAGULANTS MARKET BY COUNTRY

12.1. Middle East Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
         12.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         12.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         12.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         12.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.4. UAE
         12.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         12.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         12.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         12.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
12.5. Rest of Middle East
         12.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         12.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         12.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         12.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 13. AFRICA ANTICOAGULANTS MARKET BY COUNTRY

13.1. Africa Anticoagulants Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Anticoagulants Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
         13.3.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         13.3.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         13.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         13.3.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.4. Egypt
         13.4.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         13.4.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         13.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         13.4.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
13.5. Rest of Africa
         13.5.1. Market Revenue and Forecast By Route of Administration, 2015 - 2026 ($Million)
         13.5.2. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
         13.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
         13.5.4. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 14. COMPANY PROFILE

14.1. Bristol-Myers Squibb Company
         14.1.1. Company Snapshot
         14.1.2. Overview
         14.1.3. Financial Overview
         14.1.4. Product Portfolio
         14.1.5. Key Developments
         14.1.6. Strategies
14.2. Pfizer, Inc.
         14.2.1. Company Snapshot
         14.2.2. Overview
         14.2.3. Financial Overview
         14.2.4. Product Portfolio
         14.2.5. Key Developments
         14.2.6. Strategies
14.3. Bayer Healthcare
         14.3.1. Company Snapshot
         14.3.2. Overview
         14.3.3. Financial Overview
         14.3.4. Product Portfolio
         14.3.5. Key Developments
         14.3.6. Strategies
14.4. Sanofi
         14.4.1. Company Snapshot
         14.4.2. Overview
         14.4.3. Financial Overview
         14.4.4. Product Portfolio
         14.4.5. Key Developments
         14.4.6. Strategies
14.5. Boehringer Ingelheim International GmbH
         14.5.1. Company Snapshot
         14.5.2. Overview
         14.5.3. Financial Overview
         14.5.4. Product Portfolio
         14.5.5. Key Developments
         14.5.6. Strategies
14.6. Johnson & Johnson Services, Inc.
         14.6.1. Company Snapshot
         14.6.2. Overview
         14.6.3. Financial Overview
         14.6.4. Product Portfolio
         14.6.5. Key Developments
         14.6.6. Strategies
14.7. Daiichi Sankyo Company Limited
         14.7.1. Company Snapshot
         14.7.2. Overview
         14.7.3. Financial Overview
         14.7.4. Product Portfolio
         14.7.5. Key Developments
         14.7.6. Strategies

CHAPTER 15. RESEARCH APPROACH

15.1. Research Methodology
         15.1.1. Initial Data Search
         15.1.2. Secondary Research
         15.1.3. Primary Research
15.2. Assumptions and Scope